展望Therapeutics注册直接发行定价500万美元

2026-05-29 04:11

Outlook Therapeutics (Nasdaq: OTLK) on Thursday said it priced a registered direct offering of about 8.54 million shares of common stock at $0.5855 per share to GMS Ventures and Investments, its largest shareholder.
The offering is expected to generate gross proceeds of about $5 million before expenses and is scheduled to close on or about May 29, subject to customary closing conditions.
The biopharmaceutical company said it plans to use the proceeds, along with existing cash, for working capital and general corporate purposes.
Outlook also said it agreed to amend certain outstanding warrants held by GMS Ventures and Investments to reduce the weighted average exercise price to $0.5855 per share from $1.78 per share, effective upon closing of the offering.
Source: Press Release

More on Outlook Therapeutics